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Abstract: Stroke is a leading cause of death and disability worldwide. The importance of 
lowering blood pressure for reducing the risk of stroke is well established. However, not 
all the benefits of antihypertensive treatments in stroke can be accounted for by reductions in 
BP and there may be differences between antihypertensive classes as to which provides optimal 
protection. Dihydropyridine calcium channel blockers, such as amlodipine, and angiotensin 
receptor blockers, such as valsartan, represent the two antihypertensive drug classes with the 
strongest supportive data for the prevention of stroke. Therefore, when combination therapy is 
required, a combination of these two antihypertensive classes represents a logical approach.
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Introduction
Stroke is a leading cause of death and disability worldwide.1 It has been estimated that 
15 million people worldwide suffer a stroke each year and one-third of these individuals 
will die.2 Moreover, one-third of these stroke victims will be left permanently disabled, 
profoundly affecting their quality of life and placing a large burden on their families, 
communities and society.2 The total incidence of stroke is expected to increase 
considerably over the next two decades.1 In the European Union, for example, the 
World Health Organization-estimated number of stroke events is expected to increase 
from 1.1 million in 2000 to 1.5 million by 2025.3 In other, less developed regions of 
the world, stroke is reaching pandemic proportions as a result of rapid urbanization 
and industrialization.4
Risk factors for stroke and the importance  
of blood pressure lowering
Risk factors for stroke are classified according to whether they are modifiable or not. 
Nonmodifiable risk factors include old age, male gender, Asian and Black ethnicities, 
and strong family history. Among the well documented modifiable risk factors for 
stroke are: hypertension, cigarette smoking, diabetes, dyslipidemia, obesity, atrial 
fibrillation (AF), carotid artery stenosis, and a previous stroke, transient ischemic 
attack (TIA) or heart attack.5 In addition, left ventricular hypertrophy (LVH) and 
abnormal left ventricular geometry have been shown to be associated with increased 
risk of stroke in a multi-ethnic population.6
A prior stroke or TIA places patients at very high risk of a recurrent cerebrovas-
cular event.7 Indeed, in a population-based study of early risk of stroke after a TIA or Vascular Health and Risk Management 2009:5 594
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minor stroke, the estimated risk of recurrence at 3 months 
post event was 17.3% and 18.5%, respectively.8 In a Chinese 
patient population with ischemic stroke who were registered 
in the Nanjing Stroke Registry Program, a first-year recur-
rence rate of 11.2% was reported. This is of interest because 
data on stroke occurrence and recurrence are very limited 
in China9 and much of Asia.10 Given the global burden of 
stroke, effective therapeutic interventions aimed at primary 
and secondary prevention are needed.
Of the modifiable risk factors for stroke, hypertension 
serves as the most prevalent and powerful of risks,11 regardless 
of geographic location and ethnicity. Approximately 54% 
of strokes worldwide can be attributed to elevated blood 
pressure (BP).12 Such is the association that people with 
hypertension are 3 to 4 times more likely to suffer a stroke 
than those without hypertension.13 The relationship between 
BP and risk of first stroke is direct, continuous and inde-
pendent, with the risk increasing continuously above a BP 
of 115/75 mmHg.11 Hypertension also increases the risk of 
stroke recurrence and it has been shown that approximately 
25% to 30% of patients recovering from a stroke have raised 
BP at the time of discharge from hospital.14
There is strong and consistent evidence that lowering 
elevated BP is an important therapeutic target in the pri-
mary and secondary prevention of stroke, regardless of age, 
gender or ethnicity (Asian or White).15 A meta-analysis of 
nine randomized comparative trials found that a reduction 
in systolic blood pressure (SBP) of just 1 to 3 mmHg led 
to a reduction in risk of stroke of 20% to 30%.16 Moreover, 
in age-specific analyses from two cohort study overviews 
(the Prospective Studies Collaboration and the Asia Pacific 
Cohort Studies Collaboration),17 a 10 mmHg reduction in 
SBP was associated with a 35% reduction in the risk of 
stroke in subjects aged 60 to 69 years (Table 1).18 Simi-
lar benefits have also been shown for stroke survivors. In a 
meta-analysis including 6752 patients with a previous history 
of cerebrovascular disease (stroke or TIA), antihyperten-
sive therapy resulted in a 28% reduction in risk for stroke 
recurrence.19 Antihypertensive treatment that effectively 
reduces BP to target levels may therefore be one of the most 
important approaches for reducing the risk of stroke. Indeed, 
the importance of treatment has been demonstrated in a study 
where early discontinuation with antihypertensive therapy 
was associated with a 28% increase in the risk of stroke.20
This review will examine the evidence available for the 
use of calcium channel blockers (CCBs) and renin angio-
tensin system (RAS) blockers – with focus on angiotensin 
receptor blockers (ARBs) – in the primary and secondary 
prevention of stroke, and explore whether there is poten-
tial in this regard for dual-mechanism therapy with a 
CCB/ARB.
Antihypertensive therapy in the 
primary and secondary prevention 
of stroke
What evidence is available with CCBs?
Numerous studies have compared the effects of CCBs with 
placebo or an active treatment for preventing cerebrovas-
cular events (Table 2). Two placebo controlled trials, the 
Prospective Randomized Evaluation of the Vascular Effects 
of Norvasc Trial (PREVENT) and Systolic Hypertension in 
Europe (Syst-Eur) study have assessed the effects of CCBs 
compared with placebo for reducing the risk of stroke.21–23 
A meta-analysis of these two trials provided clear evidence 
of a reduction in stroke risk with CCBs vs placebo of 39%.18 
The Systolic Hypertension in China (Syst-China) study has 
also confirmed the benefits of the dihydropyridine CCB, 
nitrendipine, for improving prognosis in Chinese patients. 
Indeed, nitrendipine-based treatment reduced the incidence 
Table 1 Reductions in the risk of stroke related to systolic blood pressure (SBP) predicted from cohort studies and observed in clinical 
trials
Predicted effects on stroke 
of lowering SBP 10 mmHga
Observed effects on stroke with 
a reduction in SBP of 10 mmHgb
Mean age at event Estimated mean age at event
60–69 years 70–79 years Approximately 73 years
Prospective Studies Collaboration (2002) 34% 29% 31%
Asia Pacific Cohort Studies Collaboration (2003) 36% 25%
Reproduced with permission from Lawes CM, Bennett DA, Feigin VL, Rodgers  A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(4):1024–1033.18 
Copyright © 2004 Lippincott Williams & Wilkins.
aRelative risk reduction in stroke from cohort studies with a 10 mmHg lower SBP,  by age at event.
bRelative risk reduction in stroke from randomized controlled trials with a 10 mmHg reduction in SBP. Mean age at entry into trials was 63 years, and mean age at event is 
likely estimated to be a decade later (ie, 73 years).Vascular Health and Risk Management 2009:5 595
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of fatal and nonfatal stroke by 38% (hazard ratio [HR] 0.62 
[95% confidence interval (CI) 0.42–0.91]; P  0.05).24 
In addition, in the ACTION (A Coronary disease Trial 
Investigating Outcome with Nifedipine GITS) trial, a CCB 
reduced the risk of any stroke or TIA by 30% compared 
with placebo in patients with hypertension and stable 
angina.25 Following ischemic stroke, CCB treatment has been 
associated with a reduction in mortality (odds ratio [OR] 0.38 
[0.17–0.88] vs no CCB treatment) and improvements in the 
stroke impact scale-16.26
In addition to their benefits compared with placebo, 
CCBs have also been shown to provide better protection 
against fatal and nonfatal stroke than older drugs, such as 
β-blockers and diuretics.27,28 In addition, CCBs have been 
shown to provide benefit over angiotensin-converting 
enzyme inhibitors (ACEIs) (11% relative risk [RR] reduc-
tion) in a meta-analysis of 4 trials (the Appropriate Blood 
Pressure Control in Diabetes [ABCD], the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial [ALLHAT], the Fosinopril Versus Amlodipine 
Cardiovascular Events Randomized Trial [FACET] and 
the Swedish Trial in Old Patients with Hypertension 
[STOP-2].18 A meta-regression analysis has confirmed that 
CCBs are superior to ACEIs for the prevention of stroke 
(P = 0.042).29
Amlodipine
In the BP-lowering arm of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT), amlodipine-based 
treatment reduced fatal and nonfatal stroke by 23% (HR 
0.77 [0.66–0.89]; P  0.0003) compared with atenolol-
based treatment in a range of high cardiovascular (CV) 
risk patients (11% with a previous stroke or TIA) with 
uncontrolled BP (SBP  160 mmHg and/or diastolic blood 
pressure [DBP]  100 mmHg BP not on antihypertensive 
treatment or SBP  140 mmHg and/or DBP  90 mmHg; 
n = 19342).30 On average, BP levels were lower throughout 
the trial in patients allocated to amlodipine-based treatment 
compared with atenolol-based treatment (average difference 
2.7/1.9 mmHg). Although BP was the largest contributor to 
stroke events, peripheral BP measurements could not fully 
account for the treatment differences in stroke.31
The Comparison of AMlodipine vs Enalapril to Limit 
Occurrences of Thrombosis (CAMELOT) study compared 
amlodipine with enalapril or placebo in 1991 patients with 
angiographically documented coronary artery disease and 
DBP  100 mmHg. Amlodipine reduced the risk of stroke or 
TIA by 50% compared with placebo (HR 0.50 [0.19–1.32]) 
and 24% compared with enalapril (HR 0.76 [0.26–2.20]), 
although these reductions did not achieve statistical 
significance (P = 0.15 and P = 0.61, respectively), possibly 
due to the small numbers of events.32
ALLHAT compared three different antihypertensive 
regimens (amlodipine, chlorthalidone, and lisinopril) in 
33357 patients with stage 1 or 2 hypertension and at least 
one other risk factor for coronary heart disease.33 Almost one 
quarter (23%) of patients had a previous history of stroke or 
myocardial infarction (MI) at baseline. Stroke was assessed 
as a secondary endpoint and there were significantly more 
strokes for lisinopril compared with amlodipine (RR 1.23 
[1.08–1.41]; P  0.003).34 On average, follow-up BP was 
1.5/1.1 mmHg higher in patients treated with lisinopril 
compared with amlodipine.34 However, there was no sig-
nificant difference in stroke incidence between amlodipine 
and chlorthalidone (RR 0.93 [0.82–1.06]; P = 0.28) in this 
study.33
An analysis of six actively controlled trials involving 
an amlodipine treatment group (including the three trials 
described above plus the Candesartan Antihypertensive 
Survival Evaluation in Japan [CASE-J] trial, the Valsartan 
Antihypertensive Long-term Use Evaluation [VALUE] and 
the Irbesartan Diabetic Nephropathy Trial [IDNT]) showed 
that amlodipine provided more protection against stroke than 
other antihypertensive agents (OR 81 [95% CI 0.75–0.87]; 
P  0.0001).35 Moreover, the risk of stroke with amlodip-
ine was statistically less when compared with non-ARB 
antihypertensive drugs (OR 0.79 [95% CI 0.72–0.87]; 
P  0.0001) and ARB therapies separately (OR 0.84 [95% 
CI 0.73–0.97]; P = 0.02).
What evidence is available with ARBs?
The RAS
The RAS has been linked to the development and progression 
of cerebrovascular disease in patients with hypertension.36,37 
Indeed, angiotensin II is thought to induce cerebrovascular 
hypertrophy and remodeling, inhibit endothelium-dependent 
relaxation and disrupt the blood-brain barrier.36 Therefore, 
it might be assumed that RAS blockade would provide 
cerebroprotection. However, studies with ACEIs have 
produced mixed results (Table 2).
In the Heart Outcomes Prevention Evaluation (HOPE) 
study ramipril reduced all stroke by 32% (RR 0.68 
[0.56–0.84]) and fatal stroke by 61% (RR 0.39 [0.22–0.67]) 
compared with placebo in a study of 9297 patients with 
high CV risk (∼11% had a prior history of stroke).38,39 In the 
Perindopril Protection Against Recurrent Stroke Study Vascular Health and Risk Management 2009:5 596
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(PROGRESS), active treatment with perindopril monotherapy 
or perindopril plus a diuretic (indapamide) reduced stroke 
by 28% in 6105 patients with a history of stroke or TIA.40 
However, in PROGRESS, monotherapy with perindopril had 
little beneficial effect on stroke when compared with placebo, 
despite a reduction in BP of 5/3 mmHg.40 This observation 
is consistent with a meta-analysis of three smaller trials 
(Survival And Ventricular Enlargement [SAVE], Acute 
Infarction Ramipril Efficacy [AIRE] and TRAndolapril 
Cardiac Evaluation [TRACE]) which did not observe a 
beneficial effect of ACEIs on stroke compared with placebo 
(OR 1.10 [0.84–1.43]; P = 0.48) in patients with heart 
failure (HF) or left ventricular dysfunction.41
In studies with an active comparator, data supporting 
the use of ACEIs are even less convincing. In the Captopril 
Prevention Project (CAPPP), fatal/nonfatal stroke was found 
to be 1.25 times more frequent in patients randomized to 
captopril vs conventional therapy with diuretics, β-blockers 
or both,42 although a subanalysis found no difference in 
stroke between study groups in patients with diabetes.43 
In ALLHAT, lisinopril was less effective in preventing 
stroke vs chlorthalidone (RR 1.15 [1.02–1.30]; P = 0.02),33 
although interpreting these findings is confounded by the 
different BPs achieved.
It has subsequently been suggested that angiotensin II 
might have a protective effect on stroke.44–46 In an analysis of 
26 prospective randomized trials during which 7108 strokes 
occurred in 206,632 patients without HF, Boutitie et al noted 
that differences in BP do not totally account for differences 
in stroke risk and that the relative risk of stroke was 17% 
greater with agents that potentially decrease angiotensin II 
levels (β-blockers and ACEIs) compared with those that 
increase angiotensin II levels (thiazide diuretics, dihydropyri-
dine CCBs and ARBs).44 It was hypothesized that increased 
angiotensin II may act on angiotensin type 2 (AT2) receptors 
and mediate protective effects such as improving collateral 
circulation and neuronal resistance to anoxia.44 However, 
mechanistic data to support such an effect in the cerebral cir-
culation in humans are lacking and data from animal models 
should be interpreted with caution as the presence and role 
of receptors can differ from that in humans.
Stroke protection with ARBs
According to the hypothesis proposed by Boutitie et al 
ARBs should help protect against stroke as, in addition to 
lowering BP, they inhibit the negative effects of angiotensin 
type I (AT1) receptors in the cerebral circulation, but allow 
angiotensin to mediate potentially stroke-protective effects 
through the AT2 receptor. Observations from large clinical 
trials would support this suggestion.
In the Losartan Intervention For Endpoint reduction in 
hypertension (LIFE) study, losartan substantially reduced 
the rate of fatal and nonfatal stroke by 25% vs atenolol (HR 
0.75 [0.63–0.89]; P = 0⋅001) in 9193 patients with hyper-
tension and LVH.47 A small (1.1 mmHg) but significant 
difference in the reduction in systolic BP (P = 0.017) was 
observed between treatments in favor of losartan. A substudy 
of patients with LVH and isolated systolic hypertension in 
the LIFE trial demonstrated an even more impressive 40% 
stroke reduction.48 AF is a known risk factor for stroke and 
losartan reduced the incidence of stroke by 51% (HR 0.49 
[0.29–0.86]; P = 0.01) in patients with new-onset AF in the 
LIFE study.49 In the Study on Cognition and Prognosis in 
the Elderly (SCOPE), candesartan-based treatment reduced 
nonfatal stroke by 27.8% and all stroke by 23.6% compared 
with placebo in 4964 elderly patients.50 The Telmisartan 
Randomised AssessmeNt Study in ACE iNtolerant subjects 
with cardiovascular Disease (TRANSCEND) study reported 
a nonsignificant 17% reduction in stroke with telmisartan 
compared with placebo in high-risk patients who were intol-
erant to ACEIs.51 The TRANSCEND trial included a large 
proportion of patients without hypertension, in whom the 
benefits of BP lowering remains highly uncertain.
In addition to the strong data with ARBs for the primary 
prevention of stroke in placebo-controlled trials, several stud-
ies have indicated that ARBs are at least as effective as other 
antihypertensive agents for preventing stroke (Table 2). For 
example, in the CASE-J study there was no significant dif-
ference in cerebrovascular events between amlodipine- and 
candesartan-based regimens in Japanese high-risk patients 
(n = 4728) with hypertension, including approximately 
10% of patients with a history of cerebrovascular events.52 
Recently, the Ongoing Telmisartan Alone and in Combina-
tion with Ramipril Global Endpoint Trial (ONTARGET) 
programme compared the effects of an ARB, telmisartan, with 
an ACEI, ramipril, and both agents in combination, in a range 
of patients at high risk of CV disease (n = 25620). ONTAR-
GET reported no significant difference between ramipril and 
telmisartan for reducing stroke.53 In addition, a combination 
of ramipril and telmisartan provided no additional benefit 
to either monotherapy. These findings in ONTARGET may 
seem to contradict the hypothesis suggested by Boutitie et al 
ONTARGET enrolled individuals mostly at high risk of car-
diac events rather than cerebrovascular events, where ramipril 
has already been shown to improve stroke in these patients.38 
ACEIs are known to reduce cardiac risk and complications.39 Vascular Health and Risk Management 2009:5 599
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Thus, it may be that many of the strokes in HOPE and 
ONTARGET occurred secondary to cardiac complications 
and this would explain some of the benefit of these agents 
on stroke. A recent meta-analysis covering 49924 patients 
in 6 trials (ONTARGET, Valsartan In Acute Myocardial 
Infarction Trial [VALIANT], Evaluation of Losartan In The 
Elderly study [ELITE] I and II, OPtimal Trial In Myocardial 
infarction with the Angiotensin II Antagonist Losartan 
[OPTIMAAL] and Diabetics Exposed to Telmisartan and 
enalaprIL [DETAIL]) comparing ACEIs and ARBs head-
to-head noted that, despite similar effects on MI, ARBs were 
associated with an 8% lower risk of stroke compared with 
ACEIs (OR 0.92 [95% CI 0.85–0.99]; P = 0.036).54
The benefits of ARBs for the prevention of secondary 
stroke are less well known and are undergoing intense 
scrutiny. Indeed, it has long been debated whether elevated 
BP should be lowered in the acute phase of stroke as it 
is feared that lowering BP would reduce cerebral blood 
perfusion. The Acute Candesartan Cilexetil Therapy in 
Stroke Survivors (ACCESS) study assessed the safety of a 
modest BP reduction by candesartan in the early treatment 
of stroke (n = 342) and showed significant reductions in 
12-month mortality and vascular events with candesartan 
compared with placebo (OR 0.475 [95% CI 0.252–0.895]).55 
The Scandinavian Candesartan Acute Stroke Trial (SCAST) 
is designed to compare the effects of an ARB (candesartan) 
or placebo on CV morbidity and mortality in approximately 
2500 patients with acute stroke (30 hours) and elevated 
SBP (140 mmHg).56
The Morbidity and Mortality After Stroke, Eprosar-
tan compared with nitrendipine for Secondary Preven-
tion (MOSES) study was the first to compare an ARB 
with a short-acting CCB in a population of patients with 
hypertension and a history of cerebrovascular events. The 
trial reported a significant (P = 0.026) 25% reduction in 
cerebrovascular events with eprosartan compared with 
nitrendipine, despite similar reductions in BP.57 Thus, the 
MOSES and ACCESS studies demonstrate that ARBs are 
effective for the secondary prevention of stroke. In contrast, 
the PRoFESS (Prevention Regimen for Effectively Avoiding 
Second Strokes) study, the largest randomized double-blind 
secondary stroke prevention trial to date,58 did not find any 
significant benefit of telmisartan treatment compared with 
placebo on recurrent stroke in 20332 patients with an isch-
emic stroke within the last 120 days and who were stable 
(HR 0.95 [95% CI 0.86–1.04]; P = 0.23).59 The lack of a 
significant benefit between telmisartan and placebo in these 
patients could be due to methodological considerations, 
such as the inclusion of patients with low BP (baseline 
SBP was 144 ± 17 mmHg) and carotid plaques. However, 
a prespecified subgroup analyses indicated no heterogeneity 
of effects on stroke across baseline SBP categories (135, 
135 to 150 and 150 mmHg). The presence of a J-curve 
relationship between BP and stroke, similar to that reported 
for a composite of all-cause mortality, nonfatal MI and 
nonfatal stroke and BP in patients with hypertension and 
coronary artery disease in the INternational VErapamil SR-
trandolapril Study (INVEST),60 is unlikely to account for the 
lack of benefit with telmisartan in PRoFESS. Indeed, several 
studies have noted that a reduction in SBP to 140 mmHg 
is associated with a reduced risk of stroke in patients with a 
prior stroke/TIA61 or in high-risk hypertension.62 Moreover, 
an analysis of PROGRESS observed similar risk reduction 
in each of four subgroups defined by baseline BP of less 
than 120, 120 to 139, 140 to 159, and 160 mmHg or greater 
(P = 0.5 for homogeneity), indicating that achieving low 
BP levels should not be a concern in patients with prior 
cerebrovascular disease.63
In the Japanese Investigation of Kinetic Evaluation in 
Hypertensive Event and Remodelling Treatment (JIKEI 
HEART) study, valsartan has been examined in a Japanese 
population (n = 4728) with hypertension and other CV dis-
ease (patients with a cerebrovascular event in the previous 3 
months were excluded) who were receiving usual treatment. 
Of patients who received valsartan on top of usual treat-
ment, 29 had stroke (or TIA), compared with 48 in patients 
receiving non-ARB-based treatment (HR 0.60; P = 0.0280).64 
The VALUE trial compared the effects of the ARB valsartan 
with the CCB amlodipine on cardiac morbidity and mortal-
ity in 15245 patients with hypertension and high CV risk.65 
Almost 20% of the patients in VALUE had a history of 
stroke or TIA at baseline. No significant difference in the 
incidence of stroke was noted between the two treatment 
arms.62,65 In the VALUE study, an ARB was shown to reduce 
AF significantly more than amlodipine,66 although this was 
not associated with a significant reduction in stroke,65 pos-
sibly due to the small numbers of patients with these events. 
Thus, valsartan and other ARBs appear to reduce the risk of 
stroke more than placebo and to a similar extent as CCBs in 
primary prevention populations.
In general, the cerebrovascular benefits of ARBs seem to 
be class-related rather than drug-related.54 All ARBs might 
be expected to reduce the risk of stroke. Any differences 
in stroke protection between individual trials may be 
accounted for by difference in study design and/or patient 
populations.Vascular Health and Risk Management 2009:5 600
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What is the source of the benefit 
of ARBs and CCBs on stroke?
Reductions in BP are the most important determinant of CV 
outcome, and stroke in particular.29 Most of the benefit of 
amlodipine on stroke can be explained by differences in BP 
control.35 The relationship between BP and stroke is strong 
and even small changes in BP between treatments can result 
in differences in stroke (Figure 1).16,67,68 However, there does 
appear to be a BP-independent component that contributes to 
the benefit of CCBs on stroke.31,35 Similarly, reductions in the 
incidence of stroke with ARBs in the MOSES and ACCESS 
studies occurred despite reductions in BP being similar to that 
observed with the comparators used, suggesting that these 
agents also have some BP-independent benefits. Preclinical 
studies also support a BP-independent effect of ARBs on 
stroke. In normotensive rats, pretreatment of an ARB at a 
subantihypertensive dose was more effective than an ACEI 
for reducing infarct size and neurological deficits following 
transient focal ischemia.69
There are several theoretical mechanisms whereby ARBs 
and CCBs might prevent stroke beyond BP reductions. For 
example, increased carotid intima-media thickness (CIMT) is 
associated with an increased risk for stroke 70 and it is known 
that CCBs can reduce carotid intima-media thickening to a 
greater degree than observed with ACEIs, despite similar 
reductions in BP.71 It has been suggested that this effect on 
CIMT might explain the superior protection against stroke 
with these agents.71 ARBs have also been shown to reduce 
CIMT in patients with hypertension,72–74 an effect greater 
than observed with atenolol despite similar reductions in 
BP.72 This effect on CIMT observed with ARBs is thought 
to be mediated by improvements in nitric oxide production 
and decreases in oxidative stress.74
Increased left ventricular mass (LVM) is a risk factor 
for stroke.6 Increased LVM is also a risk factor for AF,75 a 
known cause of stroke.76,77 Thus, a beneficial effect of ARBs 
and CCBs on LVH relative to other antihypertensive agents 
could also explain the strong supportive data for stroke pre-
vention with these agents. Indeed, in a meta-analysis of the 
effects of antihypertensive treatment on LVM, CCBs and 
ARBs were reported to reduce LVM index by 11% and 13%, 
respectively, which are numerically greater reductions than 
those observed with other antihypertensive agents.78
Changes in central aortic pressure but not peripheral BP 
could explain some differences between CCBs and other 
agents. Despite similar brachial pressures, amlodipine-based 
treatment reduced central SBP more than atenolol-based 
treatment in the ASCOT Conduit Artery Function Evaluation 
(CAFÉ) substudy.79 It has been suggested that heart rate is 
a major determinant of the difference between central and 
brachial BP and might account for the less effective lowering 
of central BP with atenolol.80 Thus, the effect on central BP 
and heart rate could account for some of the difference in 
stroke between atenolol and amlodipine in ASCOT. When 
assessing possible relationships of BP and stroke, many 
studies are limited by the use of sitting BP determined in the 
clinic. However, there are other BP parameters, such as cen-
tral BP, night-time and 24-hour BP, BP variability and heart 
rate, which might also contribute to treatment differences in 
stroke, and further studies are required.
Finally, experiments in animals suggest that ARBs and 
CCBs might have BP-independent effects that might influ-
ence stroke outcomes. For example, studies in spontaneously 
hypertensive rats suggest that ARB treatment can reduce 
inflammation in cerebral microvessels81 and normalize the 
cerebral blood flow following ischemia.82 Moreover, in a rat 
model of cerebral ischemia, ARB treatment reduced middle 
cerebral artery (MCA) media thickness and infarct area 
following occlusion of MCA.83 Studies in rats also showed 
that the protection in cerebral circulation by improving 
cerebral blood flow autoregulation and reducing superoxide 
production, occurred with doses that do not reduce BP.84 
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Figure 1 Relationship between SBP and stroke. Reprinted from The Lancet, 362, 
Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. effects of 
different blood-pressure-lowering regimens on major cardiovascular events: results 
of prospectively-designed overviews of randomised trials, 1527–1535.67 Copyright © 
2003, with permission from elsevier.
Notes: A, CCB vs placebo; B, ACei vs placebo; C, more intensive vs less intensive 
BP-lowering; D, ARB vs control; e, ACei vs CCB; F, CCB vs diuretic or β-blocker; 
G,   ACei vs diuretic and β-blocker.
Abbreviations: ACei, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; BP, blood pressure; CCB, calcium channel blocker; SBP, systolic 
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A similar effect has also been observed with amlodipine 
in ApoE knockout mice model of stroke.85 Although these 
effects have been observed in animal models, these data 
should be cautiously translated to humans where these 
mechanisms have not been readily observed.
Although it is possible to speculate about the various 
possible cerebroprotective mechanisms of CCBs and ARBs, 
reductions in BP are key in preventing stroke. Moreover, 
caution should be used when comparing and interpreting 
differences in stroke reductions between clinical trials, 
as differences in trial design and selection criteria may 
influence the data. A meta-analysis of head-to head ACEI 
and ARB trials noting a slight benefit in stroke prevention 
with ARBs could not attribute any mechanistic basis to the 
cerebrovascular protection with ARBs, and it cannot be 
excluded that differences in blood pressure accounted for 
this observation.54
Potential of combination therapy
As indicated previously, the relationship between BP 
reductions and the risk of stroke is well established (Figure 1).67 
It has been suggested, therefore, that rapid, sustained 
reductions in BP are necessary for the optimal prevention 
of stroke in patients with hypertension.45 Indeed, in VALUE 
the BP response after 1 month predicted CV events and 
survival.62 Combination therapy has been suggested as an 
approach to achieve large, rapid reductions in BP and help 
optimize the reduction in stroke risk.45
Few studies have assessed the benefits of combination 
therapy compared with monotherapy. The Felodipine Event 
Reduction (FEVER) study has compared a combination 
therapy (hydrochlorothiazide [HCTZ]/felodipine extended 
release) with monotherapy (HCTZ/placebo) in 9800 Chinese 
patients with hypertension and other CV risk factors. It was 
noted that addition of felodipine extended release to HCTZ 
treatment reduced BP by an additional 4.2/2.1 mmHg and 
reduced the incidence of fatal/nonfatal stroke by 27% vs 
HCTZ/placebo.86 Thus, these studies would support the 
use of greater BP reductions with combination therapy to 
provide greater reductions in the risk of stroke. In contrast, 
combining an ARB and an ACEI in ONTARGET provided 
no additional benefit over monotherapy for reducing stroke 
despite an incremental reduction in BP of 2.4/1.4 mmHg over 
ramipril monotherapy.53 Therefore, the choice of agents for 
combination may be an important consideration.
The  Avoiding  Cardiovascular  events  through 
COMbination therapy in Patients Living with Systolic 
Hypertension (ACCOMPLISH) trial compared the clinical 
benefits of two single-pill combinations of antihypertensive 
agents (benazepril/HCTZ and amlodipine/benazepril) on 
CV mortality and morbidity in high-risk patients with 
hypertension.87 It was noted that the CCB/ACEI combination 
decreased CV morbidity and mortality significantly more 
than the ACEI/diuretic (20% relative risk reduction; 
P  0.001) despite similar reductions in BP.88 There were 
numerically fewer strokes (fatal and nonfatal) with the 
CCB/ACEI compared with the CCB/diuretic (16% risk 
reduction) in ACCOMPLISH although this did not achieve 
statistical significance (P = 0.16), and it may be that there 
were insufficient events to establish a difference between 
treatments in this outcome.
In the JIKEI HEART study, addition of valsartan to 
conventional therapy was more effective at reducing stroke 
compared with non-ARB-based therapy.64 Given that the 
majority of patients were receiving antihypertensive agents 
at baseline, this may suggest that that ARB-based combina-
tions might have some utility in preventing stroke compared 
with non-ARB-based combinations.
In PROGRESS, combination therapy with perindopril 
and indapamide reduced BP by 12/5 mmHg and lowered 
the risk of recurrent stroke by 43% compared with placebo. 
However, single drug therapy with perindopril reduced BP 
by only 5/3 mmHg and resulted in no significant reduction 
in recurrent stroke risk.40,89 On the basis of these data, the 
US JNC VII guidelines recommend either treatment with 
a diuretic, an ACE inhibitor or both agents in combination 
for the prevention of recurrent stroke.90 However, these 
recommendations were made before the results of studies 
investigating the use of ARBs for the prevention of 
secondary stroke (MOSES, ACCESS and PROFeSS) 
were published. The ESH-ESC guidelines recognize that 
antihypertensive treatment markedly reduces the incidence 
of stroke recurrence in patients with a history of stroke or 
TIA, and a BP goal of 130/80 mmHg is recommended.91 
Since evidence from trials suggests that the benefit 
predominantly depends on BP lowering, the ESH-ESC 
guidelines indicate that all available drugs and ‘rational’ 
combinations can be used.91 The benefits of BP lowering 
in the setting of acute stroke requires more research 
and current recommendations are that antihypertensive 
treatment should start when poststroke clinical conditions 
are stable, usually several days after the event.91 Both JNC 
VII and ESH-ESC guidelines recognize that combination 
therapy is required to reduce BP to recommended levels 
in a large proportion of patients.90,91 In addition, more 
evidence is needed before the specific cerebrovascular Vascular Health and Risk Management 2009:5 602
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protective properties of individual agents or particular 
combinations are established.
Rationale for a CCB/ARB single-pill 
combination for stroke prevention
Multiple regulatory pathways are involved in the regulation of 
BP, and therefore combinations of agents that act by different 
mechanisms can have complementary actions and be more 
effective at reducing BP than monotherapy.92 To optimize the 
benefits on stroke prevention it seems logical, when combin-
ing agents, to employ agents that (1) have complementary 
effects, (2) are effective at reducing BP, (3) might possess 
BP-independent effects, such as those discussed earlier, and 
(4) are associated with strong supportive evidence for the 
prevention of stoke. As indicated earlier, protection against 
stroke was greater with ARBs than with ACEIs.54
Individually, amlodipine and ARBs seem to possess 
strong clinical trial data for antihypertensive agents in the 
protection against stroke.93 Clinical studies have demon-
strated that a combination of valsartan and amlodipine is an 
effective antihypertensive strategy capable of reducing BP 
more effectively than either treatment as monotherapy.94–96 
Indeed, amlodipine/valsartan 5 to 10/160 mg reduces BP 
across all stages of hypertension, with reductions from 
baseline in mean sitting systolic BP of 20, 30 and 36 to 
43 mmHg, respectively, in patients with mild, moderate and 
severe hypertension.94,96,97 The large BP reductions with this 
combination coupled with the data supporting the protective 
effect of these agents as monotherapy would suggest that 
this combination might be an effective approach for stroke 
prevention. Indeed, in the JIKEI HEART study, a large pro-
portion (67%) of patients in this study were also receiving 
a CCB and valsartan therapy reduced the risk of stroke by 
40% compared with non-ARB-based therapy.64 These data 
may suggest that combining valsartan with a CCB, such 
as amlodipine, has potential for protecting against stroke. 
However, studies on this combination in the context of stroke 
prevention have not been conducted to date.
Finally, the presence of CCB/ARB combinations in 
single-pill formulation may have indirect benefits. It is known 
that the use of single-pill antihypertensive combinations can 
improve persistence with therapy beyond that provided by 
free combinations.98 Patients who persist on antihypertensive 
therapy have been reported to have a 28% reduction in 
the relative risk of stroke compared with patients who 
do not persist with therapy.20 Thus, the use of single-pill 
antihypertensive combinations may help to reduce stroke 
through improvements in adherence.
Concluding remarks
In conclusion, antihypertensive agents can reduce the risk 
of stroke, predominantly by reductions in BP. However, 
there may be some differences in stroke protection between 
antihypertensive treatments, which may not be explained 
solely by differences in BP. Possible mechanisms for this 
additional benefit might include reductions in CIMT, LVH or 
central BP, or improvements in cerebral blood flow autoregu-
lation. ARBs and CCBs have particularly strong supportive 
data for a protective effect against stroke. The choice of these 
agents or combinations of these agents could help to optimize 
the cerebrovascular benefits of antihypertensive treatment. 
However, further studies are needed to confirm the benefits 
of different combination strategies on stroke.
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